| Literature DB >> 33371186 |
Athanasia Apsemidou1, Miriam Antonie Füller2, Evgeny A Idelevich3,4, Oliver Kurzai5,6, Athanasios Tragiannidis1,2, Andreas H Groll2.
Abstract
Candida lusitaniae is a rare cause of candidemia that is known for its unique capability to rapidly acquire resistance to amphotericin B. We report the case of an adolescent with grade IV graft-vs.-host disease after hematopoietic cell transplantation who developed catheter-associated C. lusitaniae candidemia while on therapeutic doses of liposomal amphotericin B. We review the epidemiology of C. lusitaniae bloodstream infections in adult and pediatric patients, the development of resistance, and its role in breakthrough candidemia. Appropriate species identification, in vitro susceptibility testing, and source control are pivotal to optimal management of C. lusitaniae candidemia. Initial antifungal therapy may consist of an echinocandin and be guided by in vitro susceptibility and clinical response.Entities:
Keywords: Candida lusitaniae; breakthrough; candidemia; infection; resistance; transplantation
Year: 2020 PMID: 33371186 PMCID: PMC7766689 DOI: 10.3390/jof6040380
Source DB: PubMed Journal: J Fungi (Basel) ISSN: 2309-608X